Crohn Disease (CD)

Immunology
2
Pipeline Programs
3
Companies
33
Clinical Trials
9 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

Eli Lilly and Company
OMVOHApproved
mirikizumab-mrkz
Eli Lilly and Company
Interleukin-23 Antagonist [EPC]subcutaneous2023

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
OMVOH(Mirikizumab)Phase 4Monoclonal Antibody5 trials
Active Trials
NCT07446101Not Yet Recruiting450Est. Feb 2027
NCT07186101Recruiting252Est. Mar 2029
NCT06864403Recruiting25Est. Apr 2027
+2 more trials
Celltrion
CelltrionKorea - Incheon
1 program
Healing Circuits™ sessionsN/A
Amgen
AmgenTHOUSAND OAKS, CA
1 program
Healing Circuits™ sessionsN/A1 trial
Active Trials
NCT07013578Recruiting100Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab
Eli Lilly and CompanyMirikizumab

Showing 15 of 33 trials with date data

Clinical Trials (33)

Total enrollment: 13,977 patients across 33 trials

NCT06864403Eli Lilly and CompanyMirikizumab

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Start: Aug 2025Est. completion: Apr 202725 patients
Phase 4Recruiting
NCT07059130Eli Lilly and CompanyMirikizumab

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

Start: Jul 2025Est. completion: Feb 2026150 patients
Phase 4Not Yet Recruiting
NCT06937099Eli Lilly and CompanyMirikizumab

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Start: Jun 2025Est. completion: May 2028290 patients
Phase 3Recruiting
NCT06937086Eli Lilly and CompanyMirikizumab

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Start: Jun 2025Est. completion: Apr 2028350 patients
Phase 3Recruiting
NCT05509777Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Start: Mar 2024Est. completion: Apr 202890 patients
Phase 3Recruiting
NCT05784246Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Start: Nov 2023Est. completion: Aug 202660 patients
Phase 3Recruiting
NCT05767021Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Start: May 2023Est. completion: Apr 2026172 patients
Phase 3Active Not Recruiting
NCT04844606Eli Lilly and CompanyMirikizumab

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Start: May 2021Est. completion: Dec 2030150 patients
Phase 3Recruiting
NCT04469062Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis

Start: Apr 2021Est. completion: Jun 20240
Phase 3Withdrawn
NCT04232553Eli Lilly and CompanyMirikizumab

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Start: Jun 2020Est. completion: Apr 2027996 patients
Phase 3Active Not Recruiting
NCT03926130Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Start: Jul 2019Est. completion: Oct 20231,158 patients
Phase 3Completed
NCT03524092Eli Lilly and CompanyMirikizumab

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Start: Oct 2018Est. completion: Feb 20251,177 patients
Phase 3Completed
NCT03556202Eli Lilly and CompanyMirikizumab

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Start: Sep 2018Est. completion: Feb 20221,936 patients
Phase 3Terminated
NCT03519945Eli Lilly and CompanyMirikizumab

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Start: Jul 2018Est. completion: Dec 20271,063 patients
Phase 3Active Not Recruiting
NCT03535194Eli Lilly and CompanyMirikizumab

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Start: Jun 2018Est. completion: Jun 20201,484 patients
Phase 3Completed
NCT03518086Eli Lilly and CompanyMirikizumab

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Start: Jun 2018Est. completion: May 20241,281 patients
Phase 3Completed
NCT03482011Eli Lilly and CompanyMirikizumab

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

Start: Apr 2018Est. completion: Jan 2020530 patients
Phase 3Completed
NCT07186101Eli Lilly and CompanyMirikizumab

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Start: Nov 2025Est. completion: Mar 2029252 patients
Phase 2Recruiting
NCT06598943Eli Lilly and CompanyMirikizumab

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Start: Oct 2024Est. completion: Sep 2028140 patients
Phase 2Recruiting
NCT02891226Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

Start: Dec 2016Est. completion: Feb 2021191 patients
Phase 2Completed
NCT02589665Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Start: Dec 2015Est. completion: May 2019249 patients
Phase 2Completed
NCT07446101Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

Start: Mar 2026Est. completion: Feb 2027450 patients
Phase 1Not Yet Recruiting
NCT06475729Eli Lilly and CompanyMirikizumab

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

Start: Jun 2024Est. completion: Dec 2024498 patients
Phase 1Completed
NCT05515601Eli Lilly and CompanyMirikizumab

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

Start: Aug 2022Est. completion: Feb 2023396 patients
Phase 1Completed
NCT05069896Eli Lilly and CompanyMirikizumab

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

Start: Oct 2021Est. completion: Jun 2022237 patients
Phase 1Completed
NCT04607733Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab in Healthy Participants

Start: Nov 2020Est. completion: May 2021240 patients
Phase 1Completed
NCT04548219Eli Lilly and CompanyMirikizumab

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

Start: Sep 2020Est. completion: Jan 202160 patients
Phase 1Completed
NCT04137380Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab in Healthy Chinese Participants

Start: Dec 2019Est. completion: Dec 202060 patients
Phase 1Completed
NCT03718884Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab in Participants With Plaque Psoriasis

Start: Oct 2018Est. completion: Oct 201929 patients
Phase 1Completed
NCT03053622Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) Injection in Healthy Participants

Start: Apr 2017Est. completion: Apr 201867 patients
Phase 1Completed
NCT02568423Eli Lilly and CompanyMirikizumab

A Study of Mirikizumab (LY3074828) in Healthy Participants

Start: Dec 2015Est. completion: Oct 201851 patients
Phase 1Completed
NCT01947933Eli Lilly and CompanyMirikizumab

A Safety Study of Mirikizumab (LY3074828)

Start: Oct 2013Est. completion: Feb 201545 patients
Phase 1Completed
NCT07013578AmgenHealing Circuits™ sessions

TIDHI Mental Health in IBD Patients Study

Start: Jul 2025Est. completion: Jul 2027100 patients
N/ARecruiting

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
13h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
14h ago

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
Yesterday
$137K - $236K/yr

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
Yesterday

Supply Chain and Procurement Controller

Ferring Pharmaceuticals
Hvidovre, Denmark
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 actively recruiting trials targeting 13,977 patients
3 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)